Bicara Therapeutics Inc.
BCAX
$15.07
$0.533.65%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
4/28/2025
-
Ticker Report
4/27/2025
-
MarketBeat
4/27/2025
-
MarketBeat
4/26/2025
-
MarketBeat
4/23/2025
-
MarketBeat
4/23/2025
-
GuruFocus
4/23/2025
-
GuruFocus
4/23/2025
-
Globe Newswire
4/19/2025
-
MarketBeat
4/19/2025
-
MarketBeat
4/19/2025
-
Ticker Report
4/19/2025
-
MarketBeat
4/17/2025
-
GuruFocus
4/17/2025
-
The Fly
4/12/2025
-
MarketBeat
4/11/2025
-
MarketBeat
4/10/2025
-
MarketBeat
4/9/2025
-
MarketBeat
4/7/2025
-
Ticker Report
4/7/2025
-
TipRanks Financial Blog
4/6/2025
-
MarketBeat
4/5/2025
-
Ticker Report
4/4/2025
-
MarketBeat
4/3/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Aug 18 and 22 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617 468 4219
Address
116 Huntington Avenue
Boston, MA 02116
Boston, MA 02116
Country
Year Founded
Business Description
Sector
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. The company’s lead program is ficerafusp alfa, a...
more